Skip to main
EPRX
EPRX logo

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals Inc. has gained a favorable outlook as the announcement regarding CLDX effectively eliminates a potential competitor in eosinophilic esophagitis (EoE), thereby validating the company's innovative approach with its product EP-104GI. The encouraging results from the Phase 1b/2a portion of the RESOLVE trial indicate durable drug release and improved treatment outcomes even nine months after administration at higher doses, bolstering the product's potential efficacy. Furthermore, a successful Phase 2b outcome could pave the way for a streamlined Phase 3 trial aimed for early 2027, aiming to solidify regulatory approval with a patient cohort of 150 to 300, representing a strong strategic milestone for the company.

Bears say

Eupraxia Pharmaceuticals faces significant risks associated with potential cross-border supply chain disruptions and tariffs, which could adversely impact its operational efficiency and cost structure. The company's focus on developing innovative pharmaceutical alternatives may not offset the financial burdens arising from these external factors, particularly in a competitive biotechnology landscape. Additionally, the reliance on proprietary technology and the clinical-stage nature of its products may result in extended timelines for achieving market approval, further contributing to uncertainty regarding future revenue generation.

EPRX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 2 analysts, EPRX has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.